Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer.

Upcoming Event: Sept 26-30, 2014: European Society for Medical Oncology (ESMO)

» Upcoming Event: Sept 4-6, 2014: ASCO 2014 Breast Cancer Symposium

» UT Southwestern's Rolf Brekken, PhD, speaks with The Cancer Research Institute about bavituximab

In The News

Monday, August 11, 2014

Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
Monday, July 14, 2014

Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments
Monday, July 7, 2014

Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014

More News »

Copyright © 2003-2014 Peregrine Pharmaceuticals Inc., All Rights Reserved	Disclaimer Safe Harbor